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“Science is the poetry of reality.” 
 
Richard Dawkins 
 
 
  
ABSTRACT    v
Abstract 
Background: Each year, around the world, more than 230 million patients 
have surgery. Improvements in healthcare have resulted in older and sicker pa-
tients undergoing surgical interventions. As a result, surgical safety has become 
a global public-health concern. Cognitive impairment has emerged as the most 
common postoperative complication in these older individuals. The etiology of 
this condition is unknown, although episodes of hypooxygenation/hypoperfu-
sion, negative impacts of anesthetic drugs, cerebral microemboli from cardio-
pulmonary bypass during cardiac surgery, and neuroinflammation have been 
implicated.  
 
Aims: To explore the mechanisms behind this postoperative cognitive dys-
function, we focused on the impacts of surgery on: 1) blood-brain barrier 
(BBB) function; 2) changes in the levels of systemic and neuroinflammatory 
biomarkers; and 3) biochemical evidence of perioperative neuronal damage. We 
also evaluated whether an unfavorable late neurocognitive postoperative out-
come was associated with an enhanced neuroinflammatory response or cerebral 
biomarker evidence of neuronal injury. Finally, we investigated whether a single 
perioperative dose of methylprednisolone attenuates the postoperative BBB 
dysfunction and prevents neuroinflammation after cardiac surgery. 
 
Methods: We conducted a prospective, observational, two-center study with 
patients who were undergoing elective major orthopedic surgery. Cognitive 
function was evaluated preoperatively, at discharge, and at 3 months postoper-
atively. Biochemical markers of inflammation, neuronal damage, brain amyloi-
dosis, and BBB function were measured in cerebrospinal fluid (CSF) and blood 
samples during the initial 48 hours postoperatively. Furthermore, in a prospec-
tive, randomized, double-blinded, double-armed study, 30 patients who were 
undergoing elective open heart surgery were randomized to a single dose of 
either methylprednisolone or placebo. CSF and blood samples obtained pre-
operatively and at 24 hours after surgery were analyzed for biochemical markers 
of inflammation, neuronal damage, and BBB function. 
 
Results: Disruption of BBB function, manifested as an increased CSF to se-
rum albumin quotient, was detected after both cardiac and orthopedic surger-
ies. Both orthopedic and cardiac surgeries were associated with a pronounced 
increase in inflammatory biomarkers in the CSF and blood. The CSF inflam-
matory biomarkers were significantly associated with long-term cognitive de-
cline 3 months after orthopedic surgery.  
. 
  
Surgery resulted in increased levels of biomarkers of neuronal damage and brain am-
yloidosis in the CSF and blood, although there was no association between these 
biomarkers and postoperative cognitive decline. None of preoperative biomarkers 
were predictive of postoperative cognitive decline. Methylprednisolone attenuated 
the systemic inflammatory reaction but not the BBB dysfunction that followed car-
diac surgery. 
 
Conclusions: Surgery induces a profound systemic inflammatory reaction, followed 
by disruption of the BBB. Single-dose treatment with a potent corticosteroid did not 
attenuate the BBB disruption. The postoperative neuroinflammatory reaction, as-
sessed as biomarker levels in the CSF, is significantly associated with long-term cog-
nitive decline, whereas the increased postoperative markers of neuronal damage 
showed no such association 
 
Keywords: Anesthesia, blood-brain barrier, brain amyloidosis, cardiac surgery, or-
thopedic surgery, inflammation, neuroinflammation, neuronal damage, cognitive de-
cline, postoperative cognitive dysfunction 
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Sammanfattning på svenska 
I takt med industrialiseringen har det skett en demografisk förskjutning mot en allt 
äldre befolkning. Detta i kombination med de senaste decenniernas medicinska fram-
steg har medfört att det utförs successivt mer avancerade kirurgiska ingrepp på allt 
äldre patienter. Det har länge varit känt att det finns en risk för kognitiv nedsättning, 
dvs försämring av hjärnans högre funktioner, efter kirurgiska ingrepp hos framförallt 
äldre patienter. Hur omfattande problemet är har först uppenbarats på senare tid, när 
större studier har visat att ca 25% av patienterna har kognitiv nedsättning första 
veckan efter kirurgi och efter 3 månader har 10% kvarstående problem. Detta gör 
kognitiv nedsättning till den vanligaste komplikationen efter kirurgi. Mekanismerna 
bakom tillståndet är dock okända. Det har framförts teorier om att orsaken skulle 
vara långtidseffekter av anestesimedel, små blodproppar från hjärt-lungmaskinen till 
hjärnan vid hjärtkirurgi, påskyndande av demensutveckling, perioder med lågt blod-
tryck under operationen eller en inflammatorisk reaktion i hjärnan. 
 Vi har i dessa studier utforskat bakomliggande mekanismer, med fokus framförallt 
på en möjlig inflammatorisk orsak. I samband med kirurgi sker alltid cellskada och 
de ämnen som frisätts aktiverar vårt medfödda immunsystem vilket ger en lokal in-
flammatorisk reaktion som i sig är en viktig del i läkningsprocessen. Blod-hjärn bar-
riären har som uppgift att strikt reglera vilka ämnen som passerar från blodet till 
centrala nervsystemet, där det i normalfallet är en mycket låg grad av immunologisk 
aktivitet. Inflammatoriska signalsubstanser som kommer ut i blodbanan efter kirurgi 
ger en påverkan på kroppens övriga organ och har visat sig, i experimentella studier, 
via en ökad genomsläpplighet i blod-hjärn barriären, kunna sprida inflammationen 
även till hjärnan. 
 Genom att undersöka hur nivåerna av olika substanser i blod och ryggmärgsvätska 
påverkas av kirurgi har vi studerat blod-hjärn barriärens funktion, tecken till nerv-
cellsskada, påverkan på demensmarkörer och grad av inflammation. Vi har undersökt 
patienters kognitiva funktion före operationen, innan hemgång samt vid ett återbesök 
3 månader efter det kirurgiska ingreppet. I ett försök att minska inflammation och 
påverkan på blod-hjärn barriären gavs patienter en engångsdos metylprednisolon (en 
inflammationsdämpande steroid) före hjärtoperation.  
 Vi fann en uttalad ökning av inflammatoriska markörer i blod följt av ökad ge-
nomsläpplighet i blod-hjärn barriären efter kirurgi. Under de första 48 timmarna efter 
ortopedisk kirurgi skilde sig sedan det inflammatoriska svaret i hjärnan tydligt mellan 
de patienter som efter tre månader kom att ha kvarstående kognitiv nedsättning och 
de som återhämtade funktionen. Metylprednisolon minskade inte påverkan på blod-
hjärn barriären eller inflammationen i hjärnan.
  I blod och ryggmärgsvätska ökade nivåerna av ämnen som tyder på nervcellsskada, 
men det fanns inget samband mellan nivåerna av dessa markörer och utebliven kog-
nitiv återhämtning. Vi hittade ingen markör i proverna som togs före operationen 
som skulle kunna förutsäga patienternas kognitiva påverkan på kort eller lång sikt.  
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1 .  INTRODUCT ION    1
1. Introduction 
1.1 Background 
The mind is a precious, yet fragile, gift of evolution. For most of us, the deterioration 
of our mental abilities is a far more frightening prospect than debilitation of the rest 
of the body. Nevertheless, and even though reports of mental side-effects of surgery 
and anesthesia date back to the birth of modern surgery[1, 2], this subject remained 
for a long time largely unexplored.  
1.1.1  “Pumpheads” in cardiac surgery 
In the 1950’s, the first heart-lung machines were introduced in clinical practice, mak-
ing open-heart surgery feasible[3]. Over time, concerns were raised regarding the po-
tential side-effects of the use of the heart-lung machine, as some patients exhibited 
impaired cognitive functions after otherwise uneventful surgery. This was confirmed 
in a number of studies, in which the incidence of cognitive impairment 1 week fol-
lowing surgery was found to be in the range of 50%–70%[4]. However, there was no 
consensus in the definition of cognitive deficit, which tests should be used, or the 
timing of the tests. By the late 1980’s, the concept emerged of postoperative cognitive 
dysfunction (POCD), signifying a patient who did not return to their baseline cogni-
tion level after surgery. A systematic review revealed that 23% of patients experienced 
a cognitive deficit 2 months after surgery[5]. This was attributed to the use of cardi-
opulmonary bypass (CPB) in cardiac surgery, and cardiac surgery performed without 
the use of CPB (off-pump surgery) was suggested as a way to reduce this risk. Sub-
sequent studies, however, failed to show a neuroprotective effect of using off-pump 
surgery[6]. 
1.1.2 The 1990’s 
The subject of POCD attracted renewed interest with a publication in 1998 from the 
International Study of Post-Operative Cognitive Dysfunction (ISPOCD) group. In 
this study, more than 1,000 patients who were undergoing different types of non-
cardiac surgery were examined both before and after surgery using a comprehensive 
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test battery. Perioperative neurocognitive decline was detected in 26% of the patients 
1 week after surgery, and in 10% of the patients 3 months after surgery[7]. These 
results suggested that POCD was a common complication, not only following cardiac 
surgery, but also after general surgery. 
1.2 Perioperative neurologic complications 
The broad spectrum of possible perioperative neurological complications is, for the 
sake of completeness, briefly discussed in this section. Thereafter, this thesis will fo-
cus on POCD. 
 Worldwide, more than 230 million patients undergo surgery annually, with the 
consequence that surgical safety has become a significant global public-health con-
cern[8]. At the same time, we are facing an increasingly aging population. This, com-
bined with more effective and safer anesthesia and surgery, has resulted in older and 
sicker patients being more likely than ever before to be exposed to surgical interven-
tions. In the USA, 15% of the population are older than 65 years and they receive 
35% of all in-patient surgeries[9]. 
Elderly patients have increased risks of postoperative complications and mortal-
ity[10]. These complications include the perioperative neurocognitive disorder of 
acute delirium and POCD. Delirium is now recognized as the most common com-
plication following surgery in older adults, with an incidence of up to 50% [11]. It is 
associated with adverse outcomes, including prolonged hospitalization, loss of func-
tional independence, impaired cognitive function, and death[12-14]. 
The occurrence of stroke after cardiac surgery significantly prolongs the postop-
erative hospital stay (11 versus 7 days), as well as the intensive care unit stay (3 versus 
2 days)[15]. Furthermore, in-hospital mortality is significantly higher for patients who 
suffer a perioperative stroke, as compared to those who do not (14.4% versus 
2.7%)[15]. 
Cognitive decline is associated with decreased quality of life 1 and 5 years after cardiac 
surgery[16, 17]. It is associated with increased mortality, risk of premature departure 
from the labor market, and dependency on social welfare payments after non-cardiac 
surgery[18]. 
1.2.1 Stroke 
Stroke, which is a leading global cause of premature death and disability, is responsi-
ble for 6.2 million deaths annually. Since, treatment options are few, clinical efforts 
focus mainly on the prevention and treatment of stroke and the other sequelae of 
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cerebrovascular disease. In the perioperative setting, patients are at particular risk of 
stroke, with the highest incidence seen for cardiovascular surgery (range of 1.9–9.7% 
in different studies)[19], while in non-cardiovascular, non-neurological surgery the 
stroke incidence is in the range of 0.1–1.9%[20]. 
1.2.2 Delirium 
Delirium is an acute and fluctuating alteration of the mental state of the subject, in-
volving an altered level of consciousness and disturbance in attention (i.e. reduced 
ability to direct, focus, sustain, and shift attention). It is defined by either the 10th 
revision of the International Statistical Classification of Diseases and Related Health 
Problems (ICD 10) or by the Diagnostic and Statistical Manual of Mental Disorders, 
5th Edition (DSM- 5). Postoperative delirium (POD) occurs up to 5 days after sur-
gery. Delirium takes a hypoactive (decreased alertness and motor activity) or hyper-
active (agitated and combative) form. If not specifically looked for in the diagnostic 
workup, the hypoactive form often goes undetected[21]. 
The use of established diagnostic tools is recommended. The Confusion Assess-
ment Method for the Intensive Care Unit (CAM-ICU) has shown strong reliability 
and validity for assessing delirium[22]. The CAM-ICU evaluates mental status, inat-
tention, disorganized thinking, and altered level of consciousness. 
1.2.3 Postoperative cognitive dysfunction 
Cognitive functions are mental processes that allow us to perform various tasks. The 
processes include learning, information processing, flexibility, problem solving, deci-
sion making, reasoning, remembering, and attention. POCD involves a decline of the 
cognitive abilities of the patient following a surgical procedure.  
In contrast to delirium and dementia, there has been a lack of consensus as to 
how POCD should be defined. Consequently, there are major differences in meth-
odology between the performed studies in terms of which test batteries are used, the 
interval between sessions, which endpoints are analyzed, and which statistical meth-
ods are applied. This makes comparisons of the studies challenging, and creates dif-
ficulties with respect to drawing definitive conclusions about various interventions 
or risk factors.   
The previously mentioned ISPOCD-1 study introduced the concept of an age-
matched control group to adjust for learning effects from repeated tests[7]. 
In 2018, an updated nomenclature for POCD was presented[23], which aimed to 
harmonize the criteria and nomenclature to other conditions of cognitive decline 
NEUROCHEMICAL AND COGNITIVE AFTERMATHS OF SURGERY 
4   1.  INTRODUCT ION  
 
from the DSM-5 and ICD-10. This results in a clinical nomenclature, with each cat-
egory requiring symptoms or complaints from the patient or from relatives. Efforts 
to define perioperative neurocognitive disorder research criteria are underway, but 
not yet published. 
1.2.4 Dementia 
Dementia, which is a chronic disorder of the mental processes resulting from brain 
disease or injury and affecting cognitive domains such as memory, personality 
changes, and impaired reasoning, has a global prevalence of more than 50 million 
persons[24]. 
Alzheimer’s disease (AD) is a fatal, progressive neurodegenerative disorder, ac-
counting for the majority of dementia cases. 
A recent case-control study based on the Swedish Twin Registry found no clear 
evidence for increased risk of dementia after exposure to surgery and anesthesia[25].  
 
1.3 Risks, etiologies, and mechanisms of postopera-
tive cognitive dysfunction 
1.3.1 Risk factors 
According to the results of the ISPOCD-1 study, increasing age, fewer years of for-
mal education, longer duration of surgery, and complications (re-operation, infection, 
respiratory complications) are all factors that increase the risk of POCD at 1 week, 
while only age remains a risk factor for POCD 3 months after general surgery[7]. 
Furthermore, preoperative cognitive impairment is associated with an increased risk 
of POCD[26].  
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1.3.2 General anesthesia and surgery 
To determine whether general anesthesia (GA) itself is a risk factor for POCD, sev-
eral studies have compared patients who underwent surgical interventions that in-
volved GA or non-GA methods, such as regional anesthesia or sedation. 
In 2003, Rasmussen and colleagues enrolled 428 elderly patients and found no 
significant difference in the incidence of cognitive dysfunction 3 months after oper-
ations performed with either GA or regional anesthesia[27]. Repeated studies under-
taken since then have failed to identify GA as a risk factor for POCD[28, 29]. 
A recent study described a significant increase in the levels of plasma biomarkers 
of neuronal injury after exposure to GA and surgery, suggesting that surgery under 
GA may induce neuronal injury[30]. However, in that study, postoperative cognitive 
performance was not measured. 
Animal studies have shown how an isolated peripheral surgical trauma activates 
the innate immune system, releasing mediators that disrupt the integrity of the BBB 
[31], allowing the migration of macrophages into the central nervous system, resulting 
in neuroinflammation and subsequent cognitive impairment[32]. 
1.3.3 Anesthetic agents and depth of anesthesia 
Several studies have evaluated whether the risk of POCD differs with GA using in-
halational agents, as compared to GA with total intravenous anesthesia (TIVA). A 
recent meta-analysis has shown low-grade evidence for a risk-reducing effect of 
TIVA[33]. Further studies on this topic are underway. Depth of anesthesia is another 
proposed risk factor for POCD, although monitoring and adjusting the level of an-
esthesia has hitherto proven unsuccessful  in terms of preventing POCD[34].  
1.3.4 Cerebral perfusion and oxygenation 
Cerebral hypoperfusion and hypooxygenation, which are possible consequences of 
intraoperative systemic hypotension and can lead to brain damage, were not identi-
fied as risk factors in the ISPOCD study[7]. An association between prolonged epi-
sodes of cerebral desaturation during cardiac surgery (measured with a non-invasive 
cerebral oximeter) and early cognitive decline has been demonstrated[35].   
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1.3.5 Genetics 
The polymorphic apolipoprotein E (ApoE), which is a lipid-binding protein that is 
involved in the build-up of myelin sheets and cell membranes, has been implicated 
in the repair of neuronal injury. The gene that encodes ApoE exists in three allelic 
isoforms: ApoE-epsilon 2, 3 and 4. The isoform ApoE-epsilon 4 is strongly associ-
ated with AD[36]. A meta-analysis carried out in 2014 concluded that there is an 
association between the carrier status of the ApoE-epsilon 4 allele and the risk of 
POCD at 1 week postoperatively[37].  
1.3.6 Cardiac surgery, use of heart-lung machine 
CPB, which exposes the blood to foreign materials and carries the risk of solid or 
gaseous cerebral microemboli, has been considered a major risk factor, although stud-
ies have failed to show any difference in the incidence of POCD between on-pump 
and off-pump surgeries[6, 38].  
To avoid gaseous microemboli after open chamber cardiac valve operation, many 
centers flood the open cardiac chamber with the more soluble gas carbon dioxide 
during the procedure. However, a randomized trial failed to find a protective effect 
of carbon dioxide usage on cognitive decline[39]. 
1.3.7 Alzheimer’s disease pathology 
Hallmark changes of neurochemical biomarkers in patients with AD include in-
creased levels of cerebrospinal fluid (CSF) total-Tau (t-Tau), phosphorylated-Tau (p-
Tau), neurofilament light chain (NFL), and decreased levels of amyloid β1-42 and 
amyloid β1-40 (Aβ1-42 and Aβ1-40).  
Patients scheduled for CABG who subsequently developed POCD had preoper-
atively significantly lower plasma levels of Aβ1-42 and Aβ1-40[40]. Patients under-
going total hip or knee replacement in spinal anesthesia who had lower CSF Aβ/Tau 
ratios had a higher risk of postoperative delirium[41]. 
There are also indications that surgery, per se, induces changes in AD biomarkers. 
Patients were found to have increased levels of CSF Aβ1-42 after cardiac surgery[42]. 
Anckarsäter found increased concentrations of CSF t-Tau and no change in the CSF 
level of Aβ1-42 after knee arthroplasty[43].   
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1.4 Brain and Barrier 
1.4.1 History and background 
Evolution has gone to great lengths to protect the brain from harm. The brain is 
surrounded by a thick skull and immersed in protective CSF, both of which are im-
portant defenses against physical injury. The blood-brain barrier (BBB), which pro-
tects the brain from circulating toxins and pathogens, arises from the selective 
properties of the capillary vessels in the CNS, acting to restrict the entry of potentially 
harmful substances, while allowing the passage of necessary nutrients. 
The concept of the BBB emerged from the late 19th Century experiments of the 
German physician, and later Nobel Prize winner, Paul Ehrlich. Injecting dye into the 
bloodstream of a mouse, he found that the dye did not stain the parenchyma of the 
brain. This led his student, the Berlin physician Lewandowski, to formulate the theory 
that the capillary wall in the brain forms a barrier to certain molecules. In the 1960s, 
the invention of electron microscopy allowed researchers to visualize the key struc-
tures in the morphology of the barrier, the endothelial tight junctions.  
1.4.2 The neurovascular unit 
The neurovascular unit (NVU) is a dynamic structure in the CNS that consists of 
vascular endothelial cells, pericytes, astrocyte endfeet, and neurons (Figure 1). It has 
a critical function in regulating CNS homeostasis by modulating cerebral blood flow, 
and by influencing the permeability properties of the BBB. 
Blood vessels consist of endothelial cells and mural cells (mainly pericytes). The 
endothelial cells are largely responsible for maintaining the properties of the BBB. In 
the CNS, they are held together by tight junctions, creating a high-resistance barrier 
and limiting the paracellular flux of molecules and ions. This movement is instead 
mainly controlled by two types of active transport mechanisms. The first type con-
sists of various efflux pumps, transporting lipophilic substances back to the intravas-
cular lumen and thus preventing diffusion across the cell membrane. The second type 
takes care of the transport of nutrients into the CNS and the removal of waste prod-
ucts therefrom. 
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Residing on the abluminal surface of the endothelium, the pericytes contain con-
tractile proteins that allow them to contract so as to control the diameter of the ca-
pillary, and thus the blood flow.  
 
The astrocytes are the conveyors of neuronal signaling to the vasculature. They 
have specialized processes (endfeet) that extend from the cell body to cover most of 
the basement membrane surface area surrounding the endothelial cells and pericytes. 
Connections between the astrocyte and neuron allow for the coordination of blood 
flow with neuronal activity. Astrocytes also secrete factors with barrier-promoting or 
barrier-disrupting effects depending on their interactions with neurons and endothe-
lial cells. 
 
1.4.3 Immune privileged organ? 
The term “immune-privileged” implies that certain sites in body, e.g., the placenta / 
fetus complex and the testicles, have the ability to harbor antigens without eliciting 
an inflammatory response.  
In the healthy organism, the CNS has an extremely low level of immune surveil-
lance, the parenchyma being almost devoid of lymphocytes and neutrophils. The 
concept of the CNS as one of the immune-privileged organs has, however, been 
challenged. A growing body of evidence suggests that there is a strong linkage be-
tween systemic immune responses and the cells of the CNS.   
Figure 1. The neurovascular unit 
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Microglia are derived from peripheral macrophages and display a ramified mor-
phology in their CNS resting state. They are believed to scan continuously the sur-
rounding environment to detect extracellular changes in the environment that might 
be harmful to neural cells. When activated, the microglia undergo morphologic 
changes, shifting from their ramified phenotype to becoming enlarged and stumpy. 
They then proliferate, acquire phagocytic abilities, and release proinflammatory cyto-
kines. This is normally a self-limiting process that is designed to remove cellular de-
bris and restore homeostasis.  
The endothelial cells of the NVU have an extremely low expression level of leu-
kocyte adhesion molecules (LAMs), such as e-selectin and intercellular adhesion mol-
ecule-1 (ICAM-1) [44].  This prevents the entry of immune cells from the blood into 
the parenchyma under normal circumstances.  
1.4.4 BBB dysfunction 
It is now evident that disruption of the BBB is a major component of many neuro-
logical disorders, including stroke, dementia, traumatic brain injury, and multiple scle-
rosis[45]. In the evolutionary perspective, this was probably a beneficial response to, 
for example, trauma, a self-limiting process of healing and restoration. However, 
given the new spectrum of diseases in the modern era,  BBB disruption may be del-
eterious, leading to dysregulation, altered signal homeostasis and inappropriate in-
flammation in the CNS, progressing to neuronal dysfunction and neurodegeneration. 
During neuroinflammatory diseases, leukocyte adhesion molecule (LAM) expres-
sion on the vascular endothelial cells is increased, thereby promoting leukocyte mi-
gration across the endothelium[46]. As part of the inflammatory reaction, astrocytes 
release matrix metalloproteinases (MMPs), which have been shown in animal models 
to promote the breakdown of tight junctions and the basal membrane, thereby al-
lowing circulating immune cells to enter the brain[47].  
1.4.5 Surgery and the BBB 
Animal studies have shown how peripheral surgery activates the innate immune sys-
tem[48], inducing a rapid BBB disruption via the proinflammatory cytokine tumor 
necrosis factor-α (TNF-α), facilitating macrophage migration into the CNS and re-
sulting in decline in cognitive function, a process that was prevented by disabling the 
action of TNF-α[32]. 
Reinsfelt and coworkers found that cardiac surgery triggered biochemical signs of 
BBB dysfunction, measured as an increase in the ratio of CSF-albumin to serum-
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albumin[49]. Furthermore, cardiac surgery is known to be associated with a transient 
cerebral edema[50], possibly as a result of increased BBB permeability[51]. 
 
1.4.6 Assessing BBB function 
The 66.5-kDa protein albumin is widely accepted as the optimal candidate marker for 
measurement of BBB function. This is because it is synthesized in the liver, it is not 
catabolized within the CNS, and it is unable to diffuse across the intact BBB. The 
albumin concentrations in the CSF are dependent upon active transport across the 
vascular endothelium, in a vesicle-mediated transcellular movement known as 
transcytosis. Consequently, the Gold standard for functional assessment of BBB sta-
tus is to measure the CSF-albumin to serum-albumin ratio.  
Different imaging techniques have been used to detect BBB damage, potentially 
adding information as to the location of the leakage. Computed tomography (CT) 
has the drawback of involving a rather high level of exposure to x-rays. Positron 
emission tomography (PET) requires the use of an isotope with a short half-life. 
Magnetic resonance imaging (MRI), which is increasingly used, uses a paramagnetic 
gadolinium-based contrast agent whose molecules leak from the intravascular space 
to the interstitial space depending on the extent of BBB damage [52]. 
1.5 Inflammation 
A basic concept of any living organism is the constant striving to maintain homeo-
stasis and structural integrity. The inflammatory reaction is the innate immune sys-
tem’s ancient and hardcoded response to a wide variety of perceived dangers. This 
rapidly induced first line of defense is triggered by both endogenous and exogenous 
factors, such as tissue damage and microorganisms, respectively.  
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Figure 2 shows how the inflammatory reaction can be initiated by diverse signals, 
including pathogen-associated molecular patterns (PAMPs), which comprise evolu-
tionarily conserved microbial-specific components shared by most pathogens (e.g.,  
lipopolysaccharide (LPS) and bacterial DNA), and damage-associated molecular pat-
terns (DAMPs), which are released by damaged and dying cells. These patterns are 
recognized by a limited number of invariant pattern recognition receptors (PRRs), 
which activate microbicidal and proinflammatory responses and trigger the phyloge-
netically younger adaptive immune system. PRRs are expressed not only on the hem-
atopoietic cells involved in innate immune responses (including macrophages, mast 
cells and neutrophils), but also on vascular and epithelial cells. The succeeding in-
flammatory cascade has local as well as systemic effects. 
 
The local symptoms of inflammation were described by the Roman scholar Aulus 
Cornelius Celsus, in the 1st Century AD, as having the cardinal signs of rubor (red-
ness), tumor (swelling), calor (heat), and dolor (pain).  
The systemic effects include elevated body temperature, effects on the circulatory 
system, as well as the behavioral change known as sickness behavior, which is char-
acterized by lethargy, depression, malaise, loss of appetite and sleepiness [53]. All of 
these responses are geared to reorganize the organism's priorities to cope with trauma 
Figure 2. The inflammatory reaction 
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and disease. In severe and unresolved cases, inflammation can result in persistent 
organ dysfunction and, subsequently, death.    
1.5.1 Inflammation and surgery 
Major surgery exposes us to trauma of an extent that, set in an evolutionary perspec-
tive, is equivalent to certain death, so we cannot assume that the systemic response 
is appropriate in today’s setting. Surgery and other aseptic traumas initiate a profound 
systemic inflammatory response[54], which ultimately is designed to promote healing 
and the restoration of homeostasis.    
1.5.2 Inflammation and cardiac surgery 
Cardiac surgery has some features that potentially lead to even more pronounced 
inflammation than is seen with general surgery. In addition to the release of DAMPs 
from the surgery per se, CPB exposes the blood to foreign materials in the extracor-
poreal circuit, which causes significant systemic inflammation and increases the levels 
of proinflammatory cytokines[55, 56]. The heparin-protamine complex formed as a 
consequence of anticoagulant reversal after CPB can activate the complement cas-
cade[57]. Cardiac ischemia/reperfusion injury induces cytokine and chemokine pro-
duction[58]. In a significant number of patients, this situation develops into a 
postoperative systemic inflammatory response syndrome with fever, organ dysfunc-
tion, and cardiovascular instability[55]. 
As part of the routine care in many cardiac surgery centers, potent and long-acting 
steroids are administered prophylactically to attenuate this systemic inflammatory re-
sponse. Nevertheless, two large randomized trials on the preventive effects of ster-
oids in cardiac surgery have shown no reduction in postoperative mortality or major 
morbidity compared with placebo[59, 60]. In contrast, in a 2017 study, Glumac and 
coworkers demonstrated a reduced risk of early (5–7 days) POCD after treatment 
with a lower dose of dexamethasone administered 10 hours before cardiac sur-
gery[61].  
1.5.3 Neuroinflammation 
Blood-borne inflammatory mediators invoke degradation of the BBB, migration of 
monocyte-derived macrophages into the brain parenchyma, and a 
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neuroinflammatory response[32]. Increased levels of inflammatory cytokines are de-
tected in the CSF after general surgery[62], as well as after cardiac surgery[49].  
In the first imaging study of postoperative neuroinflammation, Forsberg and col-
leagues used positron emission tomography (PET) and a radioligand that was selec-
tive for the translocator protein expressed by microglia[63]. A suppressive response 
on Days 3–4 was followed by microglial activation at 3 months in the subset of pa-
tients with cognitive decline. 
 
1.6 Biochemical markers  
Markers of inflammation and CNS affection are measured in the blood and in the 
CSF. CSF, which is the clear liquid surrounding the brain and spinal cord, is secreted 
by the choroid plexuses located in the cerebral ventricles. The CSF has a high turno-
ver rate with a volume of 80–150 ml and a production level of 500 ml/day. Some 
proteins with high expression within the CNS are also detectable in the blood, albeit 
at very low concentrations. 
 
 
 
 
 
Figure 3. Biomarkers of BBB function, neuronal inflammation and injury 
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1.6.1 Inflammatory biomarkers 
The inflammatory cascade involves numerous substances (cytokines) with diverse, 
more or less well-known roles. Maintaining the balance between pro-and anti-inflam-
matory factors is a delicate task and many mediators seem to have counteracting 
functions in different phases of the inflammatory process. 
Interleukin-6 (IL-6), IL-8, IL-1β and TNF-α are among the most extensively stud-
ied cytokines in the surgery-induced inflammation setting. Substantial increases in the 
levels of pro- and anti-inflammatory biomarkers are detected in the serum and CSF 
after knee and hip replacement surgery[62], as well as after cardiac surgery [49]. 
1.6.2 S-100B 
S-100B is a calcium-binding protein that is present mainly in the cytoplasm of mature 
perivascular astrocytes with a serum half-life of 20–25 minutes. It is, however, also 
expressed in non-neuronal cells, such as hepatocytes, myocytes, and melanocytes, and 
in adipose tissue, which means that extracranial sources can contribute to elevated 
serum levels of S-100B. As a marker of brain injury, it has shown correlations to both 
CT findings and unfavorable functional outcomes after traumatic brain injury[64]. S-
100B is present at increased levels after cardiac surgery, as a sign of glial cell injury 
and BBB damage[49]. 
1.6.3 Neuron-specific enolase 
NSE is an enzyme that is involved in glycolysis, and is, despite its name, present not 
only in neurons but also in erythrocytes and endocrine cells. Its high sensitivity to 
hemolysis severely limits its usefulness as a brain injury biomarker, particularly in 
cardiac surgery. However, the CSF level of NSE correlates with mortality after severe 
traumatic brain injury[65]. The half-life of NSE in serum is estimated to be 30 hours. 
1.6.4 Tau 
Tau is a family of neuronal proteins, having 6 isoforms that are involved in the as-
sembly and maintenance of the microtubule structures in neuronal cells. The Tau 
protein is abundant in the thin, nonmyelinated axons of cortical interneurons. Aggre-
gations of insoluble phosphorylated Tau (p-Tau) in neurofibrillary tangles (NFTs), 
are a diagnostic marker of AD.  
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Total-Tau (t-Tau) in CSF is correlated with outcome in patients with traumatic 
brain injury[66], and CSF t-Tau is also elevated in AD. Plasma t-Tau and CSF t-Tau 
levels have been shown to have a poor correlation to each other[67]. 
1.6.5 Neurofilament light chain 
Neurofilaments are, like microtubules, part of the neuronal cytoskeleton. The neuro-
filament light chain (NFL) subunit, together with its medium and heavy counterparts, 
determine the axonal caliber and, thus, the axonal velocity. NFL is expressed exclu-
sively by central and peripheral neurons and is most abundant in the large-caliber 
myelinated axons that project into deeper brain layers and the spinal cord. There is a 
strong correlation between the plasma and CSF levels of NFL[68]. 
NFL is known to have a serum half-life of several weeks[69]. Following ischemic 
stroke, the levels of NFL in the CSF and serum increase continuously during the first 
3 weeks[70]. In a study of patients after neurosurgical trauma, CSF and serum NFL 
peaked after 1 month[71]. 
1.6.6 Glial fibrillary acidic protein 
GFAP is a CNS-specific cytoskeletal protein that is almost exclusively expressed in 
astrocytes. It is not yet as well studied as S-100B but the levels of GFAP have been 
correlated to the severity of traumatic brain injury[72].  
1.6.7 Amyloid-β (Aβ) 
Aβ1-42, which is the 42-amino acid isoform of β-amyloid, is the major component 
of senile plaques, which are characteristic of AD pathology. Aβ1-42 is a cleavage 
product of amyloid precursor protein (APP) with no known physiologic function. 
While APP is expressed and metabolized in many cell types, it is concentrated in the 
neuronal synapses, where Aβ1-42 secretion is at the highest level. 
Patients with AD have decreased levels of CSF Aβ1-42, and these levels are in-
versely correlated to the number of amyloid plaques. Plasma Aβ1-42 is emerging as 
a possible AD screening tool, although extracerebral sources may make interpretation 
difficult, as a significant source of systemic Aβ seems to be activated platelets [73]. 
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2. Aims 
I. To investigate whether orthopedic surgery or cardiac surgery induces per-
meability changes in the BBB  
II. To investigate the systemic and neuroinflammatory responses to cardiac 
and orthopedic surgeries  
III. To define the association between the neuroinflammatory response and 
long-term postoperative decline in patients after orthopedic surgery 
IV. To determine whether orthopedic surgery causes neural injury or brain am-
yloidosis 
V. To examine the biochemical evidence for neuronal damage or brain amy-
loidosis as a mechanism for cognitive decline after orthopedic surgery 
VI. To assess the potentials of preoperative biomarkers of neuroinflammation, 
brain injury and amyloidosis to predict unfavorable neurocognitive out-
comes from orthopedic surgery 
VII. To test whether a perioperative single dose of methylprednisolone can at-
tenuate the proposed postoperative BBB dysfunction and prevent neuroin-
flammation after cardiac surgery. 
. 
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3. Patients and methods  
Recruiting patients for clinical studies can be a challenging task, especially when the 
studies involve invasive procedures, such as CSF collection. Thus, a common de-
nominator in these studies is that many patients were called, but few were chosen (or 
rather choose to participate). 
 
3.1 Papers I and II 
Papers I and II are both concerned with the NEUPORT study and will thus be 
described together.   
3.1.1 Study design 
The NEUPORT study was a prospective, observational, two-center investigation. 
The study protocol was reviewed and approved by the Regional Ethics Committee 
in Stockholm, Sweden (Dnr. 2013/2297-31/4, 2014/834-32), and the study was reg-
istered at www.clinicaltrials.gov (Id: NCT02759965). 
3.1.2 Inclusion, exclusion criteria 
Patients who were scheduled for total hip or knee arthroplasty at either Karolinska 
University Hospital, Stockholm or Sahlgrenska University Hospital, Mölndal were 
screened for eligibility. After providing signed informed and written consent, 34 pa-
tients were eventually included in the study. As the focus of the study was neuropsy-
chological outcomes and neuroinflammation, there was an extensive list of exclusion 
criteria, including neurologic, psychiatric or neurovascular disease, treatment with 
anti-inammatory drugs, severe organ failure, coagulopathy, alcohol or drug abuse, 
poorly controlled diabetes mellitus, or autoimmune disease. Patients were preopera-
tively screened using the Mini Mental State Exam (MMSE) and patients with cogni-
tive impairment were excluded. Of the 34 patients included in the study, 7 were 
excluded. Twenty-seven patients were analyzed. Six of the patients had cognitive def-
icits after 3 months and constitute the Poor neurocognitive outcome group, while the 
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remaining 21 patients made up the Good neurocognitive outcome group. Twenty-four pa-
tients with complete datasets were included in the PCA analysis (see Section 3.5.1) 
3.1.3 Experimental protocol 
A schematic of the experimental protocol is presented in Figure 4. 
Cognitive performance was assessed on three occasions (at inclusion in the study, 
at discharge from the hospital, and at 3 months postoperatively) using the Interna-
tional Study of Postoperative Cognitive Dysfunction (ISPOCD) test battery (see Sec-
tion 3.4) 
Prior to the operation, a lumbar spinal catheter was inserted, left in place for 48 
hours and used for collecting CSF samples at the specified time-points. Spinal anes-
thesia was administered using the spinal catheter and light sedation was achieved with 
propofol infusion. Six patients received subcutaneous ketorolac intraoperatively as 
part of the postoperative pain regimen, otherwise anti-inflammatory and psycho-
tropic drugs were avoided.  
 
Figure 4 Protocol for studies described in Papers I and II 
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3.2 Paper III 
3.2.1 Study design 
We conducted a prospective, randomized, double-blinded, double-armed study. A 
randomized block design was used based on gender and type of surgery. 
The study was approved by The Gothenburg Regional Ethics Committee and the 
Swedish Medical Product Agency, and was registered at www.clinicaltrials.gov (id: 
NCT01755338) 
3.2.2 Inclusion, exclusion, randomization, and blinding criteria 
Patients were assessed on admission to the hospital and were given information and 
asked for consent (oral and written) by one of the investigators. Eligible patients were 
those who were scheduled for elective open aortic valve replacement surgery with a 
bioprosthesis due to aortic stenosis with or without concurrent coronary artery by-
pass grafting and normal preoperative left ventricular function (>50%).  Patients with 
a history of stroke were excluded. To minimize the risk for complications after lum-
bar puncture, no patients with recent treatment with thrombolytic or potent anti-
platelet drugs were included, and their preoperative and postoperative coagulation 
tests had to be normal.  
After inclusion, the 30 patients were randomized to two well-matched groups 
(Table 1 in Paper III), equal in size, using selection of closed envelopes. Preparation 
of the drugs was done by a nurse who was otherwise neither involved in the study 
nor in the care of the patients.  
3.2.3 Experimental protocol 
 
A schematic of the experimental protocol is presented in Figure 5. 
On two occasions, the day before surgery and approximately 24 hours after sur-
gery, a lumbar puncture was performed and the obtained CSF sample, together with 
a blood sample, was sent to the neurochemistry laboratory, where it was centrifuged, 
aliquoted, and stored at −80C for later analysis. 
After induction, the patients received the study drug (either methylprednisolone 
15 mg/kg bodyweight or placebo (an equal volume of 0.9% Sodium Chloride). 
NEUROCHEMICAL AND COGNITIVE AFTERMATHS OF SURGERY 
22   3.  PAT IENT S AN D MET HODS  
 
Anesthesia, monitoring and cardiopulmonary bypass were in both groups performed 
as per the routine praxis of our unit.  
 
 
3.3 Serum and CSF biomarker analyses 
In Paper I, the samples (CSF and serum) were analyzed using a high-throughput, 
multiplex immunoassay analysis (Proseek Multiplex, Proximity Extension Assay tech-
nology, Inflammation 1 panel; Olink, Uppsala, Sweden) for the 92 established and 
exploratory inflammatory biomarkers using DNA-labelled antibody probe pairs. The 
antibodies bind to proteins in the sample and, in the next step, a polymerase chain 
reaction (PCR) reporter sequence is formed through a proximity-dependent DNA 
polymerization event. The sequence is amplified, and subsequently detected and 
quantified using Real-Time PCR. The analyzed proteins are listed in Appendix table 
1. The values for the various inflammatory variables are presented as arbitrary units 
in Log2 scale and can thus be used only for evaluating relative changes in the levels 
of the same protein. 
CSF and serum S-100B were assayed using an Electrochemiluminescence (ECL) 
immunoassay using the Modular system and the S-100B reagent kit (Roche Diagnos-
tics, Basel, Switzerland). 
Figure 5 Study protocol for Paper III 
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Glial fibrillary acidic protein (GFAP) was measured using an ELISA method [74]. 
CSF- and serum NSE were measured using an immunofluorescent assay with the 
time-resolved amplified cryptate emission (TRACE) technology (Kryptor-NSE; 
BRAHMS GmbH, Hennigsdorf, Germany). 
The CSF total-Tau (t-Tau) concentration was determined using a sandwich 
ELISA (INNOTEST hTAU Ag; Fujirebio Europe NV, Gent, Belgium), which 
measures all tau isoforms irrespective of phosphorylation status. 
The CSF-NFL concentration was determined using an enzymatic two-site immu-
noassay (UmanDiagnostics NF-light® assay; UmanDiagnostics AB, Umeå, Sweden). 
CSF-Aβ1-42 were determined using a sandwich ELISA (INNOTEST® β-amy-
loid (1-42), Fujirebio, Belgium). 
The plasma concentrations of t-Tau and Aβ1-42 and the serum concentration of 
NFL were measured using a single-molecule array technology, as described by the 
manufacturer (Quanterix, Billerica, MA), and in Paper II, the blood to CSF ratios of 
these proteins were subsequently calculated.   
Albumin levels in the CSF (mg/L) and serum (g/L) were measured by im-
munonephelometry on the IMMAGE immunochemistry system (Beckman Coulter 
Inc., Fullerton, CA, USA), and the CSF-albumin/serum-albumin ratio was subse-
quently calculated. 
The serum and CSF levels of TNF-α, IL-6 and IL-8 in Paper III were determined 
using the Human Proinflammatory II 4-Plex Assay, Ultra-Sensitive Kit, with electro-
chemiluminescent detection (Meso Scale Discovery®; Meso Scale Daiagnostics Inc. 
Rockville, MD, USA. 
 
3.4 Cognitive tests 
To assess cognitive capacity, we used the ISPOCD test battery, in which the follow-
ing four tests (Test 1 is repeated in the end) are used to measure different aspects of 
cognitive performance[7]: 1) The visual verbal learning test, based on Rey’s auditive 
recall of words[75], which tests memory capacity. Fifteen words are presented at a 
fixed rate on a computer monitor. The patients are asked to recall as many words as 
possible. 2) The concept shifting test, which is based on the trail making test of 
Halstead and Reitan[76]. This tests the ease of shifting between two similar tasks. 3) 
The Stroop Color-Word Interference Test[77], which tests for speed and attention. 
4) The letter-digit coding test, which is based on the symbol-digit substitution task 
from the Wechsler adult intelligence scale[78]. It tests the subjects’ speed of visual 
information processing. 5) Finally, the patients were tested for delayed recall of the 
15 words from the visual verbal learning test (Test 1). 
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The tests were carried out in a quiet room with only the patient and investigator 
present. Investigators were trained by the group responsible for development of the 
test battery. 
 
3.5 Statistical analysis 
3.5.1 Paper I 
Statistical analysis was performed using the SPSS for Macintosh and SAS version 9.4 
software. 
For the Power, analysis we hypothesized that there would be a significant associ-
ation between the postoperative IL-6 concentration in the CSF and a change in cog-
nitive function (combined z-score) at the first postoperative test. A correlation 
coefficient of 0.5 for the association between CSF IL-6 concentration and the z-score 
would require 25 patients to obtain a power of 80%.  
Group differences in the pre- and peri-operative characteristics were tested using 
the Mann–Whitney U-test and Fisher’s exact test. A 2-way analysis of variance 
(ANOVA) for repeated measurements was used to assess differences between the 
groups with respect to quality of sleep and the severity of postoperative pain (VAS). 
Data are presented as either mean ± standard error of the mean (SEM), median 
with interquartile range (IQR) or median (Q1-Q3) when appropriate. Changes over 
time were tested by a repeated measurements ANOVA, and paired t-tests were used 
to assess significant changes from the preoperative levels at each postoperative time-
point.  
A principal component analysis (PCA) was performed on the preoperative CSF 
and blood biomarkers. Only those markers for which more than 75% of the values 
were above the level of detection (52 of 92) were included in the PCA. A PCA can 
be regarded as a tool for compressing a large, high-dimensional dataset while retain-
ing most of the variation. Principal components (PCs) are identified, along which the 
variation in the data is maximal. The impacts of the different markers on the PC are 
reflected in the weights. The three first PCs were selected as primary outcome varia-
bles and used to create postoperative outcome variables by applying their weights to 
the Z-transformed markers at each postoperative time-point for each variable. The 
results were then subjected to a mixed model analysis to detect differences between 
the patients with or without long-term cognitive decline. The analyses of individual 
CSF and blood biomarkers were carried out with a similar model. To compare pro-
portions with positive slopes in the PC2 analysis with respect to cognitive outcome, 
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we used Fisher’s exact test. When testing the preoperative biomarkers for between-
group differences, a Bonferroni-Holm correction was applied.  
 
3.5.2 Paper II 
Statistical analysis was performed using the SPSS for Macintosh software. 
For the statistical analyses of the pre-, peri-, and post-operative patient character-
istics, see Section 3.5.1 in Paper I. Data are presented as either mean ± standard 
deviation (SD) or median with interquartile range (IQR) when appropriate. 
Postoperative longitudinal changes in the levels of the biomarkers of neuronal 
injury independent of group were analyzed using ANOVA for repeated measure-
ments. A group-time interaction analysis of covariance (ANCOVA) of the various 
neuronal injury markers was used to compare groups with poor or good cognitive 
outcomes at 3 months post-surgery, using the baseline measurements as a covariate 
to adjust for baseline differences between the groups.  
To study the correlation between CSF and blood levels of T-tau and NFL, Pear-
son correlation coefficients were calculated. 
A post-hoc Power analysis revealed that the power to detect a 40%–50% differ-
ence in peak postoperative CSF t-Tau between the groups was 0.69–0.87 at a SD of 
225 pg/ml. The power to detect a 40%–50% difference in peak CSF Aβ1-42 was 
0.64–0.82 at a SD of 275 pg/ml. 
3.5.3  Paper III 
Statistical analysis was performed using the SPSS for Macintosh software. 
A Power analysis was performed based on our previous study[49]. To detect a 
50% difference in CSF IL-8 (primary endpoint) between the groups, with a power of 
0.80 and α-value of 0.05 and a SD of 60 ng/L, 13 patients were needed in each group. 
Continuous variables were examined for normal distribution using the Shapiro-Wilk 
test and within-group differences were compared using a paired Student’s t-test or 
Wilcoxon signed-rank test when appropriate. The comparison of the placebo and 
intervention groups was tested using an unpaired t-test test or Mann-Whitney U-test. 
All data are presented as either mean ± standard deviation (SD),  median with inter-
quartile range (IQR) or median (Q1-Q3)  when appropriate. A probability level (p-
value) of less than 0.05 was considered to indicate statistical significance.  
  
NEUROCHEMICAL AND COGNITIVE AFTERMATHS OF SURGERY 
26   3.  PAT IENT S AND MET HODS  
 
 
MATTIAS DANIELSON 
 
 
4 .  RESULT S    27
4. Results 
4.1 Patient populations 
Paper I and II 
An overview of the clinical trial flowchart for Papers I and II is presented in Figure 
6. Overall, 156 patients were assessed for eligibility and 34 patients were included. Of 
these, 7 patients were not analyzed for reasons described in Figure 6, resulting in 27 
patients in the final analysis.  
The median age of the participants was 71 (10) years and the male/female ratio 
was 9/18. According to the physical status classification system of the American So-
ciety of Anesthesiologists (ASA), the patients were distributed as ASA I (healthy 
Figure 6. CONSORT diagram showing patient inclusion (Papers I and II). Source: Dan-
ielson, M. et al., Ann Neurol, 2020, Creative Commons BY 4.0 License 
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patient, 26%), ASA II (mild systemic disease, 70%) and ASA III (severe systemic 
disease, 4%). Patient demographics and comorbidities are detailed in Table 1.  
 
 
 
Table 1.  Demographic and intraoperative characteristics (Papers I and II). Values are 
median (Q1-Q3). Group differences tested by Mann–Whitney U test and Fisher exact test. 
 
 The Good and Poor neurocognitive outcome groups did not differ in terms of 
demographic variables, overall comorbidity burden, preoperative laboratory results 
or ASA physical status level. Furthermore, no differences were detected with respect 
to the intraoperative or postoperative use of sedatives, vasoactive drugs or intrave-
nous fluids. Bleeding, duration of operation and stay in the post-anesthesia care unit, 
Characteristics Good neurocognitive 
outcome (n=21) 
Poor neurocognitive  
outcome (n=6) 
p-
value 
Preoperative 
   
Age, years 71 (65-76) 68 (65-71) 0.32 
Sex, male, n (%) 
Weight, kg 
8 (38) 
80 (73.5-89) 
1 (17) 
79 (75-88.5) 
0.63 
0.93 
Height, cm 171 (167-179) 166 (163-175) 0.24 
Body Mass Index, kg/m2 26.7 (24.6-29.4) 27.9 (25.7-31.5) 0.44 
Comorbidity   
  
     Hypertension, n 11 4 0.66 
     Diabetes mellitus, type 1, n 2 0 1 
     Diabetes mellitus, type 2, n 0 1 0.22 
     Myocardial infarction, n 1 0 1 
ASA classification  I/II/III/IV, n 7/13/1/0 0/6/0/0 0.197 
Blood hemoglobin, g/l 138 (128-147) 143 (134-157) 0.41 
Serum creatinine, μmol/l 71 (62-89) 68 (47-96) 0.63 
Preoperative WBC count 6.3 (5.4-7.9) 7.7 (6.5-8.7) 0.22 
Intraoperative   
  
Medication 
     Propofol, mg 170 (80-291) 168 (75-288) 1.0 
     Fentanyl, n 4 0 0.55 
     Alfentanil, n 2 0 1.0 
     Vasopressor, n 12 5 0.36 
Intravenous fluids, ml 1200 (950-1350) 925 (750-1560) 0.44 
Duration of procedure, minutes 89 (72-102) 86 (72-101) 0.93 
Procedure   
  
     Hip replacement, n 14 5 0.63 
     Knee replacement, n 7 1 0.63 
Bleeding, ml 300 (150-450) 225 (150-550) 1.0 
Postoperative (24 hours)   
  
PACU length of stay, minutes 165 (98-225) 171 (128-579) 0.47 
Intravenous fluids, ml 1000 (750-1850) 1575 (260-2500) 0.48 
Medication   
  
     Gabapentin, n 6 2 1 
     Oral opioid, n 20 6 1 
     Intravenous opioid, n 13 3 0.66 
Post spinal puncture headache, n 0 1 0.22 
Blood patch, n 0 1 0.22 
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as well as assessment of pain and sleep quality (VAS score) did not differ between 
the two groups. One patient developed post-spinal headache, which was successfully 
treated with a blood patch. Otherwise, the post-operative period was uneventful, with 
none of the patients developing a postoperative delirium.  
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Paper III 
The clinical trial profile of Paper III is presented in Figure 7 
Sixty-six patients undergoing cardiac surgery were assessed for eligibility. Six pa-
tients did not meet the inclusion criteria, 23 patients declined to participate and in 7 
patients surgery was cancelled or postponed. Finally, 30 patients were randomized to 
receive either placebo (n=15) or methylprednisolone (n=15).  
 
 
The patients’ demographics and comorbidities are detailed in Table ൢ. 
There was no difference between the groups with respect to age, gender, body 
weight, comorbidity burden, preoperative cardiac status, EuroSCORE II or type of 
surgery performed. There were no complications related to the preoperative or post-
operative lumbar punctures. The groups were similar with respect to duration of pro-
cedure, extracorporeal circulation and aortic cross-clamp. While the perioperative 
and postoperative blood glucose levels did not differ between the groups, there was 
a statistically significant increase in insulin requirement in the methylprednisolone-
treated group.  
Assessed for eligibility (n=66)
Excluded (n=36)
¨ Not meeting inclusion criteria (n=6)
¨ Declined to participate (n=23)
¨ Operation postponed or cancelled (n=7)
Allocated to methylprednisolone (n=15)
Received allocated drug (n=15)
Allocated to placebo (n=15)
Received allocated drug (n=15)
Analyzed (n=15)
Excluded from analysis (n=0)
Randomized (n=30)
Analyzed (n=15)
Excluded from analysis (n=0)
Figure 7. CONSORT diagram showing patient inclusion (Paper III).  
Source: Danielson, M. et al., J Neuroinflammation, 2018, Creative Com-
mons BY 4.0 License 
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Table 2. Demographics, intraoperative and postoperative characteristics of the patients 
(Paper III). Values shown are mean ± SD. **p < 0.01 
 
Characteristics  Placebo 
(n=15) 
Methylprednisolone  
(n=15) 
p-
value 
Demographics 
  
 
Age, years 68.9±11 70.7±7.0  
Male sex, n 13 10  
Body weight, kg 81.1±9.0 82.5±15.7  
Height, cm 173±7.0 176±7.9  
Comorbidity 
  
 
Hypertension, n 9 9  
Previous heart surgery, n 0 0  
Atrial fibrillation/flutter, n 1 0  
Serum creatinine, μmol/l 89.7±15 88.3±20  
Cardiac status 
  
 
LVEF, % 60±4.2 61±5.8  
NYHA 
  
 
     I (n) 7 4  
     II (n) 4 9  
     III (n) 4 2  
     IV (n) 0 0  
EuroSCORE II, % 1.8±1.4 1.9±1.5  
Type of surgery 
  
 
SAVR, n 10 11  
CABG + SAVR, n 5 4  
    
Intraoperative data    
Duration of procedure, minutes 189±43 204±58 0.43 
Duration of CPB, minutes 99.4±25 115±31 0.14 
Duration of aortic cross-clamping, minutes 81.5±25 91.7±29 0.28 
Intra-operative dose of phenylephrine, mg 1.02±1.1 1.36±1.0 0.39 
Intra-operative dose of norepinephrine, mg 0.58±1.3 0.56±0.55 0.95 
    
Plasma glucose levels   0.096 
     Start of procedure, mmol/l 6.34±1.5 5.25±0.47  
     During CPB, mean, mmol/l 6.52±0.94 7.25±1.0  
     After CPB, mmol/l 7.15±0.97 8.50±1.7  
     Arrival ICU, mmol/l 6.20±0.5 7.20±1.6  
     Day 1 ICU, mmol/l 6.27±1.2 6.44±1.2  
Insulin demand U/hour, intraoperatively + ICU 1.14±0.74 2.46±1.27 0.009** 
    
Postoperative data    
Serum creatinine, μmol/l 83.9±18 94.9±21 0.14 
Vasopressor treatment, n 6 9 0.47 
Inotropic treatment, n 0 0 1.0 
Reoperation for bleeding, n 0 0 1.0 
ICU readmission, n 0 1 1.0 
Atrial fibrillation/flutter, n 5 10 0.14 
Neurologic complication, n 2 1 1.0 
Pneumonia, n 0 1 1.0 
Wound infection, n 1 1 1.0 
Other infection, n 0 2 0.48 
Length of stay in ICU, hours 24.8±14 22.7±12 0.65 
 
 
NEUROCHEMICAL AND COGNITIVE AFTERMATHS OF SURGERY 
32   4.  RESULT S  
 
There was no difference in postoperative serum creatinine, vasopressor or ino-
tropic treatment, incidence of reoperation for bleeding, risk of ICU readmission, in-
cidence of atrial fibrillation/flutter, neurologic complications, incidence of infections, 
or length of ICU/hospital stay. 
4.2 Neurocognitive outcome (Papers I and II) 
The results for neurocognitive outcome after major orthopedic surgery are shown in 
Figure 8. When discharged from the hospital (3–5 days post-surgery), 78% (21 pa-
tients) had a composite z-score of ≥1.0. At the evaluation 3 months post-surgery, 
22% (6 patients) showed a composite z-score ≥1.0 (Poor neurocognitive outcome 
group, n=6). The remaining 21 patients (78%) had a composite z-score of <1.0 
(Good neurocognitive outcome group, n=21). 
Figure 8. Neurocognitive outcomes for patients after major orthopedic surgery. Patients 
with a z-score of ≥1.0 at 3 months (n=6) constitute the Poor neurocognitive outcome 
group. Source: Danielson, M. et al., Ann Neurol, 2020, Creative Commons BY 4.0 License 
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4.3 Blood-brain barrier (Papers I and III) 
In Paper I, for the patients undergoing major orthopedic surgery, there was a signif-
icant increase in the CSF-albumin to serum-albumin ratio at 4 and 8 hours postoper-
atively (p=0.013) (Figure 9). There was no association between these changes and 
neurocognitive outcome at 3 months postoperatively. 
In Paper III, the increase in the CSF-albumin to serum-albumin ratio was more 
pronounced in the cardiac surgery patients than in the patients undergoing orthope-
dic surgery.  The CSF-albumin to serum-albumin ratio increased by 20%–25%, 24 
hours after surgery in both the control and methylprednisolone group, with no sig-
nificant difference between the groups (Figure 9). 
 
4.4 Astrocyte injury markers (Papers I and III) 
 
Two biomarkers of astrocyte injury, S-100B and GFAP, were studied in Papers I 
and III. In Paper I, the serum S-100B (p<0.001), CSF S-100B (p=0.028) and GFAP 
(p=0.005) levels all showed significant changes over time, with transient increases at 
4 and 8 hours after surgery (Figure 10). These changes were not associated with neu-
rocognitive outcome. 
Figure 9. Ratios of CSF-albumin to serum albumin in patients pre- to post-surgery. 
The time-point 0 is the preoperative value. Data are presented as mean ± SD. 
Source: pooled data from Papers I and III.  
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In Paper III, the CSF levels of S-100B and GFAP were not significantly increased 
24 hours after surgery in the placebo group. In the methylprednisolone group, CSF 
S-100B (but not GFAP) increased marginally 24 hours after surgery. The serum level 
of S-100B increased in both groups, with no significant difference between the 
groups. 
4.5 Neuronal injury markers (Papers II and III) 
The CSF to blood ratios were positive for t-Tau and NFL in Paper II (blood con-
centrations were not measured in Paper III) while the corresponding ratio for NSE 
was the opposite (higher in serum), in both Papers II and III. 
During the 48-hour postoperative period in Paper II, the level of CSF T-tau in-
creased progressively to 33% above the preoperative level (p<0.001) (Figure 11). 
Figure 10. Concentration of astrocyte injury markers in patients pre- to post-sur-
gery. The time-point 0 is the preoperative value. Data are presented as mean ± SD. 
Source: pooled data from Papers I and III 
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However, the plasma levels of t-Tau showed a transient increase, peaking at 4 hours 
post-surgery and returning to baseline at 48 hours. There was no difference between 
the Good and Poor neurocognitive outcome groups in the temporal changes in the 
levels of either CSF t-Tau (p=0.310) or plasma t-Tau (p=0.889). The plasma T-Tau 
to CSF T-tau ratio was higher in the poor neurocognitive outcome group (p=0.028) 
(Figure 5, Paper II). There was no correlation between plasma and CSF T-tau 
(r=0.015, p=0.85, Supplemental Figure 3, Paper II). 
 
In Paper III, there was a minor, albeit significant (p<0.05), increase in CSF t-Tau 24 
hours after cardiac surgery in the control group. In the overall material (Figure 11), 
as well as in the methylprednisolone group, there was a non-significant decrease in 
CSF t-Tau.  
Figure 11. Concentration of t-Tau in the CSF and plasma of patients pre- to 
post-surgery. The time-point 0 is the preoperative value. Data are presented as 
mean ± SD. Source: pooled data from Papers II and III 
Figure 12. Concentration of NFL in the CSF and serum of patients pre- to post-
surgery. The time-point 0 is the preoperative value. Data are presented as mean ± 
SD. Source: pooled data from Papers II and III 
NEUROCHEMICAL AND COGNITIVE AFTERMATHS OF SURGERY 
36   4.  RESULT S  
 
 
 
In the 48-hour sampling period after orthopedic surgery in Paper III, there was 
no significant change in CSF-NFL (p=0.188) (Figure 12).  
The serum–NFL level showed a postoperative gradual increase up to 35% of the 
preoperative level at the end of the sampling period (p=0.001) (Figure 12).  
There was no difference between the Good and Poor neurocognitive outcome 
groups with respect to changes in the levels of CSF-NFL (p=0.437), serum-NFL 
(p=0.112) or in the serum NFL to CSF NFL ratio (p=0.172) (Figure 5, Paper II). 
There was poor but significant correlation between serum and CSF NFL (r=0.26, 
p<0.001, Supplemental Figure 4, Paper II). 
In Paper III, the levels of CSF-NFL were not changed in either the placebo 
group or the methylprednisolone group after cardiac surgery. 
The CSF and serum levels of NSE both increased over the first 8–32 hours after 
orthopedic surgery (p=0.002 and p=0.009, respectively) (Figure 13), and thereafter 
declined towards the baseline level. There was no difference in NSE levels between 
the Good and Poor neurocognitive outcome groups in CSF (p=0.124) or serum 
(p=0.0612) 
 
 As shown in Paper III, while there was no significant change in the CSF levels 
of NSE, the serum levels of NSE increased in both the methylprednisolone-treated 
and placebo groups, with no significant between-group differences (p=0.36). 
 
 
Figure 13. Concentration of NSE in the CSF and serum of patients pre- to post-surgery. 
The time-point 0 is the preoperative value. Data are presented as mean ± SD. Source: 
pooled data from Papers II and III 
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4.6 Markers of brain amyloidosis (Paper II) 
In Paper II, there were significant changes in the plasma (p<0.001) and CSF 
(p=0.019) levels of Aβ1-42 over time after orthopedic surgery, with maximal levels 
observed at 48 hours (Figure 14). There was, however, no difference between the 
patients in the Good and Poor postoperative neurocognitive outcome groups with 
respect to the CSF (p=0.057) or plasma (p=0.172) levels of Aβ1-42. Neither was 
there any significant difference between the groups in terms of the preoperative levels 
of Aβ1-42 (616±321 and 496±217 pg/ml, respectively, for the patients in the Good 
and Poor postoperative neurocognitive outcome groups (p=0.40). The plasma Aβ1-
42 to CSF Aβ1-42 ratio was higher in the poor neurocognitive outcome group 
(p=0.038) (Figure 5, Paper II). 
An Aβ1-42 level <550 pg/ml in the CSF has been used as a diagnostic cutoff 
value for AD. However, this cutoff showed no prognostic value for postoperative 
cognitive decline, as 4/16 patients (25%) with Aβ1-42 levels <550 pg/ml and 2/11 
patients (18%) with Aβ1-42 levels >550 pg/ml had poor neurocognitive outcomes 
(p=1.0). Neither was there any significant difference in preoperative T-tau levels in 
CSF comparing the Good (411±163 pg/ml) and Poor (253±64 pg/ml) neurocogni-
tive outcome groups (p=0.03).    
 
 
Figure 14. Concentration of Aβ1-42 in the CSF and plasma of patients pre- to post-
surgery. The time-point 0 is the preoperative value. Data are presented as mean ± 
SD. Source: pooled data from Paper II 
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4.7 Markers of neuroinflammation 
4.7.1 Neuroinflammation and cognitive dysfunction in orthopedic sur-
gery (Paper I) 
In Paper I, 92 established and experimental inflammatory markers were analyzed in 
CSF and serum samples at six time-points: before surgery and at 4, 8, 24, 32 and 48 
hours after surgery. A PCA was performed on the pre-operative CSF and serum data, 
and outcome variables were constructed from the three first principal components 
(PC1, PC2 and PC3). The two first construct outcome variables for CSF, PC1 and 
PC2, were significantly associated with poor cognitive outcome after 3 months, with 
increases over time in PC1 (p=0.02) and PC2 (p<0.001) (Figure 15). 
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Figure 15. Pre-operative principal components 1-3 based on all 52 inflammatory bi-
omarkers, assessing the group-time interaction in CSF and serum (n=24).Source: 
Danielson, M. et.al., Ann Neurol, 2020, Creative Commons BY 4.0 License 
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When individual patient data were applied to the PC2 construct outcome variable, 
all 6 patients in the Poor neurocognitive outcome group (z-score ≥1.00) showed a 
gradual increase over time, while this pattern was only seen in 3 out of 18 patients in 
the Good neurocognitive outcome group (100% vs 17%; p=0.006) (Figure 16). 
Figure 16. Individual trajectories for the second principal component (PC2) based 
on all 52 CSF biomarkers (n=24). Individual regressions show that all patients 
with long-term cognitive decline (blue, n = 6) exhibit an increased CSF inflamma-
tory trajectory over time, as compared to only 3 of 18 patients without long-term 
cognitive decline (red, n=18) (p=0.006; z indicates individual z-score) Source: 
Danielson, M. et al., Ann Neurol, 2020, Creative Commons BY 4.0 License
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In the serum, none of the three PC construct variables were significantly associ-
ated with neurocognitive outcome (p=0.48, p=0.29 and p=0.63 for PC1, PC2 and 
PC3, respectively) (Figure 15). 
The cytokines and chemokines with the highest loadings (impact) on PC2 are 
shown in Figure 17. A common pattern emerges with separation of the groups at the 
end of the observation period, with relatively more pronounced expression (inflam-
mation) in the patients who subsequently experienced a poor neurocognitive out-
come.   
 
Figure 17. Postoperative changes in the CSF levels of two cytokines (IL6 and IL8) 
and three chemokines (CCL3, CCL8 and CXCL6) with respect to neurocognitive 
outcome (n=24). *p<0.05, **p<0.01, (*)p<0.1. Data are presented as mean ± 
standard error of the mean. Source: Danielson, M. et al., Ann Neurol, 2020, Crea-
tive Commons BY 4.0 License 
NEUROCHEMICAL AND COGNITIVE AFTERMATHS OF SURGERY 
42   4.  RESULT S  
 
4.7.2 Neuroinflammation in cardiac surgery and effects of methylpredni-
solone (Paper III) 
In Paper III, the serum levels of IL-6 and IL-8 increased markedly in the control 
group, a response that was significantly lower in the methylprednisolone group 
(p<0.001) (Figure 19 and Figure 18). The serum level of TNF-α was unaffected in 
the control group and reduced in the treatment group, a statistically significant dif-
ference (p<0.001). 
  
 
 
In the CSF samples, we found increased IL-6 levels after cardiac surgery in the 
control group, and this increase was significantly attenuated by methylprednisolone 
(p=0.001) (Figure 19). In contrast, the post-operative increase in CSF IL-8 seen in 
the control group was enhanced in the treatment group (p<0.001) (Figure 18). There 
was a post-operative increase in the CSF level of TNF-α in both groups, with no 
significant between-group difference.  
Figure 18. Individual data on the pre- and postoperative levels of serum and CSF   
IL-8 levels in the steroid-treated and control groups. Source: Danielson, M. et al., J 
Neuroinflammation, 2018, Creative Commons BY 4.0 License 
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Figure 19. Individual data on the pre- and postoperative levels of serum and CSF   
IL-6 levels in the steroid-treated and control groups. Source: Paper III. 
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5. Discussion 
This thesis aimed to explore different aspects of the secondary responses to surgery, 
particularly those involving the CNS. To this end, we have analyzed several bi-
omarkers in the blood and CSF, and using a battery of neuropsychological tests, fol-
lowed the cognitive trajectories of the patients after surgery.   
The studies in this thesis, although by no means without certain limitations (see 
Section 5.1), each explore some unique aspects of the subject matter. For the first 
time, the post-operative biomarker changes in the CNS and their relationship to long-
term neurocognitive decline have been studied in detail. Also for the first time, the 
postoperative effects on BBB function and CNS biomarkers of glucocorticoid treat-
ment have been studied.  
5.1 Methodological considerations 
Orthopedic surgery:  
In Papers I and II, the study population consists of patients who were scheduled for 
elective total hip or knee arthroplasty. As our focus was on the mechanisms behind 
the development of POCD, we excluded patients with existing severe mental and 
cognitive disorders, e.g., preoperative cognitive impairment (MMSE score <24), neu-
rovascular disease, alcohol or drug abuse or other preexisting neurologic or psychiat-
ric disease. To avoid confounding factors when analyzing the inflammatory markers, 
patients with recent or ongoing treatment with anti-inflammatory drugs were ex-
cluded, as were patients with any autoimmune disease. Any contraindication to spinal 
catheter insertion (coagulopathy, treatment with potent antithrombotic drugs or spi-
nal nerve disorders) was a disqualifying factor. 
These rather strict inclusion criteria left us with a comparatively healthy patient 
study group, which we deemed necessary to maximize the chance of achieving inter-
pretable results. Nevertheless, one should be aware of the risk that the obtained re-
sults are less generalizable. In the end, there were no differences between the two 
outcome groups with respect to demographic data. Compared with data from the 
Swedish national registries for knee and hip arthroplasty for the period 2014–2016, 
with a mean age of 68 years and 43% male patients, it appears that the mean age of 
70 years in our cohort is similar, whereas the distribution of gender is somewhat 
skewed with 33% male patients. 
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A major limitation of the present study is the small sample size, with only six 
patients in the Poor neurocognitive outcome group. This was to be expected, though, 
as the frequency of long-term POCD (22%) was similar to that reported in other 
studies. The definition of POCD varies across studies. We classified patients accord-
ing to a composite z-score >1, which corresponds to a deterioration from the base-
line level of >1 SD, thus including patients with both mild and severe cognitive 
decline.  
A single administration of bupivacaine and sufentanil via the intrathecal catheter 
was used for spinal anesthesia. Bupivacaine has been shown to have anti-inflamma-
tory properties[79, 80] and has also been associated with chemical meningitis[81, 82]. 
The potential effects of single-dose intrathecal sufentanil or perioperative intrave-
nous sedation with propofol on CSF inflammatory biomarkers are unknown. An-
other possibility is a localized inflammatory response as a result of the indwelling 
catheter, and this cannot be excluded from our data. As the anesthetic regimen for 
the two groups was uniform, it is unlikely that any differences in brain immune re-
sponses or signs of neuronal damage between the Good and Poor neurocognitive 
outcome groups can be attributed to inter-individual differences in the anesthetic 
management or as a result of the indwelling catheter. 
We examined the cognitive function at discharge from the hospital (3–5 days post-
surgery) and at 3 months postoperatively. Since early testing may be compounded by 
hospitalization, pain and the remnants of anesthetic and analgesic drugs, testing for 
POCD at 3 months postoperatively is thought to provide a more reliable index of 
cognitive decline[83]. 
One could argue that the cognitive tests should have been administered by a neu-
ropsychologist, ideally with the same one performing all the tests. We were three 
investigators who administered the tests at the two test sites. Investigators were pre-
viously trained by the group responsible for development of the ISPOCD test battery 
and the test manual was strictly followed. 
Six patients (22%) received 15–30 mg subcutaneous ketorolac, a non-steroidal 
anti-inflammatory drug, intraoperatively as part of the postoperative pain regimen at 
one center. The extent to which this might have influenced the levels of CNS or 
serum inflammatory markers is not known, although the use of ketorolac was evenly 
distributed between the Good (24%) and Poor (17%) neurocognitive outcome 
groups. 
 
Cardiac surgery: 
In Paper III, the study population consisted of 30 patients scheduled for elective 
surgical aortic valve repair due to aortic stenosis. Overall, 30% of the patients had 
coronary vessel disease and underwent concurrent CABG. Contraindications to lum-
bar puncture, recent or ongoing treatment with thrombolytic or potent anti-platelet 
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drugs or abnormal preoperative or postoperative coagulation tests were excluding 
criteria, as were severe organ dysfunction, history of neurologic disease and treatment 
with steroids or other anti-inflammatory drugs.  
To minimize the risk of systematic error, a randomized block design based on 
gender and type of surgery was used. The majority of the participants were male 
(77%), reflecting the population of patients undergoing cardiac surgery. 2013-2017, 
64.6% of the 1130 patients undergoing surgical aortic valve replacement due to aortic 
stenosis at Sahlgrenska University Hospital, were male.  
A lumbar puncture was performed the day before and approximately 24 hours 
after surgery. This postoperative time-point was chosen to allow for the detection of 
a need for a re-operation, which might include a second period of extracorporeal 
circulation (ECC) with the concurrent heparin treatment, as well as clinical and la-
boratory evaluations of coagulation status. A single postoperative CSF measurement 
obviously means that early transient changes could be missed, as one might suspect 
is the case for S-100B, when the graphs in Papers I and III (Figure 10) are compared. 
 
5.2 Ethical issues 
All studies were approved by the Regional Institutional Review Boards. All patients 
were given written and oral information about the studies and opportunities for ques-
tions and discussions. 
Patients in Papers I and II, who would normally have had their single-shot spinal 
anesthesia delivered via a 25-27G spinal needle, instead had a lumbar intrathecal cath-
eter inserted using an 18G Tuohy needle. The catheter were left in place for 48 hours. 
The larger diameter needle carries a higher risk of post-dural puncture headache[84]. 
While leaving a catheter in place reduces this risk[85], the risk probably remains 
higher than after a conventional spinal anesthesia. One patient in the study was diag-
nosed with post-dural puncture headache, which was successfully treated with an epi-
dural blood patch. 
There is always a small risk for epidural bleeding, with potentially disabling con-
sequences, in connection with a lumbar puncture. To minimize the risk, we used thin, 
less-trauma-inducing needles and repeated evaluation of coagulation tests in Paper 
III. 
A high, perioperative, single dose of corticosteroids has several potential benefits 
in relation to cardiac surgery and is a part of the standard anesthetic regimen in many 
centers, although it also has some important potential disadvantages. Mean and peak 
blood-glucose levels rise, and this has been associated with increased postoperative 
morbidity and mortality[86]. However, in the present study, plasma glucose levels 
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were maintained at acceptable levels with insulin infusion in the corticosteroid treat-
ment group. Furthermore, it has been suggested that the use of corticosteroids is 
associated with higher lactate levels, higher sensitivity to infectious agents, impaired 
wound healing, and prolonged ventilation time[87, 88]. However, the incidence of 
infections or the length of ICU or hospital stay did not differ between the groups in 
Paper III.  
 
5.3 Neuroinflammation and cognitive function af-
ter major surgery (Paper I) 
We explored the material for pre-, peri-, and post-operative differences between pa-
tients in the Good and Poor neurocognitive outcome groups to look for clues as to 
the underlying mechanism(s) that would explain the observed differences in neu-
rocognitive outcome. There were no differences in demographics or intraoperative 
characteristics between the groups with poor and good neurocognitive outcomes 
(Table 1). Although we found no associations between the preoperative levels of CSF 
or blood biomarkers and postoperative cognitive outcome, this could be due to the 
small sample size. A meta-analysis conducted in 2013 found a correlation between 
POCD and higher preoperative levels of serum IL-10 and S-100B[89].    
In line with the results of previous studies, we found a pronounced increase in 
the levels of systemic inflammatory biomarkers following surgery. In animal studies 
this has been shown to disrupt the BBB and induce a neuroinflammatory re-
sponse[32].The permeability of the BBB (measured by the CSF-albumin to serum-
albumin ratio) was significantly increased after surgery (Figure 9). The CSF levels of 
the astrocyte cell injury markers GFAP and S-100B increased significantly postoper-
atively (Figure 10). The overall CNS and blood inflammatory changes were explored 
using a principal component analysis (PCA). Between the neurocognitive outcome 
groups, there were no significant differences in the trajectories of the blood inflam-
matory biomarkers, the CSF astrocyte injury markers, or the BBB permeability 
changes.  
This brings us to the major finding in Paper I, which is that patients with long-
term postoperative cognitive decline show a differential neuroinflammatory response 
trajectory, as compared to patients with good cognitive outcomes. Patients with a 
good neurocognitive recovery have an initial relative increase in CSF inflammatory 
biomarkers, followed by a gradual decline. This is in contrast to patients with a poor 
neurocognitive recovery, who have a lower initial expression of inflammatory bi-
omarkers, followed by a continuous increase during the 48-hour study period (Figure 
15). Following this gateway analysis, a more detailed analysis of the biomarkers with 
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the highest PC loadings revealed a smaller set of CNS chemokines and cytokines that 
showed significant differences between the patients with good and poor neurocog-
nitive outcomes (Figure 17). The recurring pattern is one of significantly increased 
late inflammatory responses in patients with long-term cognitive decline.  
These findings suggest that systemic inflammation and BBB disruption are natural 
responses to major surgery but not a cause of POCD per se. With disruption of the 
BBB, a neuroinflammatory secondary response in this setting is probably inevitable, 
and it seems that a difference in inflammatory cascade timing and resolution may be 
the key to understanding the mechanisms behind long-term neurocognitive decline 
after a surgical trauma (Figure 20). During the latter stage of our sampling period, the 
Figure 20. A neuroinflammatory theory of postoperative cognitive decline. 
NEUROCHEMICAL AND COGNITIVE AFTERMATHS OF SURGERY 
50   5.  DISC USSION  
 
cerebral inflammatory activity in the Poor neurocognitive outcome group was stead-
ily increasing (Figure 15). However, what events occur after the 48 hours remain un-
clear. It is, however, interesting to note that in the previously mentioned PET study 
of Forsberg et al., in which postoperative neuroinflammation was detected using a 
radioligand that is selective for the translocator protein expressed by microglia[63], a 
late (at 3 months) upregulation of cerebral immune activity was correlated to POCD. 
A suppressive response on Days 3–4 was followed by microglial activation at 3 
months in the subset of patients with cognitive decline. 
While there was a strong association between CNS inflammatory trajectories and 
poor long-term cognitive outcome, we were unable to detect any association to the 
short-term (3–5 days) postoperative cognitive status, suggesting that other factors, 
such as persisting drug effects, pain and lack of sleep, are of greater importance when 
it comes to short-term POCD. This is in line with the findings of Hirsch and col-
leagues who, in a small study of 10 patients, found no associations between blood 
and CSF inflammatory mediator levels during the first 18 hours after surgery and 
early (1–3 days) POCD[62].  
 
 
5.4 Neuronal injury and cognitive function after 
major surgery (Paper II) 
This secondary analysis of the data collected in the NEUPORT study explores tem-
poral changes in markers of neuronal injury and brain amyloidosis and possible asso-
ciations with postoperative neurocognitive outcomes at hospital discharge and at 3 
months after major orthopedic surgery. 
The main findings of this study are that CSF and systemic levels of the neuronal 
injury markers T-tau and NSE (Figure 11, Figure 13), as well as the brain amyloidosis 
marker Aβ1-42 (Figure 14) increase post-surgery, suggesting that major orthopedic 
surgery potentially induces neuronal stress or damage. However, as there were no 
differences in the levels of release of these neuronal injury markers or Aβ1-42 be-
tween patients who developed adverse postoperative neurocognitive outcome or did 
not, it seems unlikely that adverse neurocognitive outcomes after surgery are associ-
ated with surgery-induced neuronal injury or release of the AD marker Aβ1-42. The 
postoperative levels of the plasma to CSF ratios of T-tau, and Aβ1-42 were higher in 
the poor neurocognitive outcome group, suggesting a greater perturbation of the 
BBB in this outcome group. 
Evered and coworkers studied changes in neuronal injury markers in patients un-
dergoing joint arthroplasty under general anesthesia [30] and found a gradual increase 
in the plasma level of NFL over 48 hours, while plasma T-tau peaked after 6 hours. 
In the present study, we can confirm this pattern of systemic release of neuronal 
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injury markers. However, in contrast to the study of Evered et al., our patients were 
operated under regional anesthesia, suggesting that the primary impact on the CNS 
is related to the surgical trauma rather than to general anesthesia. Furthermore, 
Evered and coworkers did not present data on the CSF levels of neuronal injury 
markers and they did not measure late neurocognitive outcome in their study, and 
therefore could not relate surgery-induced changes in plasma levels of neuronal injury 
markers to late cognitive function. 
The CSF levels of T-tau increased gradually during the 48 hours after the surgical 
procedure, while the plasma levels of T-tau showed an early peak (4 hours), corre-
sponding to the timing of the opening of the BBB (Figure 11). In contrast, we were 
unable to detect any significant changes in the CSF levels of NFL within the study 
period. However, NFL is known to have a different time-course, with a serum half-
life of several weeks[69]. Moreover, following a stroke, the levels of NFL in CSF and 
serum increase continuously during the first 3 weeks[70]. Thus, our failure to capture 
changes in the CSF levels of NFL could be due to a protracted increase in CSF-NFL 
that become apparent after the 48-hour sampling period. The increase in serum-NFL 
could be explained by the change in BBB permeability, combined with the positive 
CNS-to-serum gradient for NFL. Alternatively, the gradual increase in serum-NFL 
could be associated with surgery-induced peripheral nerve injury. There was an ab-
sent (T-tau) and poor (NFL) correlation between blood and CSF levels of these mark-
ers, suggesting that one should be cautious when evaluating surgery-induced neuronal 
injury that solely rely on blood sampling. 
Both CSF-NSE and serum-NSE showed significant changes over time (Figure 
13). Considering that there was a prominent negative CSF-to-serum gradient (higher 
concentrations in serum) and that there is an abundance of extra-cerebral sources of 
NSE (peripheral neurons, erythrocytes, platelets and neuroendocrine cells), any 
changes in NSE level, be they in the serum or CSF, must be regarded with caution. 
We found a significant and continuous increase in the CSF level of Aβ1-42 during 
the study period (Figure 14). Perioperative changes in the CSF Aβ1-42 levels are not 
well-studied. In a study of 11 patients who were undergoing idiopathic nasal CSF 
leakage correction, Tang et al. measured the CSF levels of AD biomarkers up to 48 
hours postoperatively; they found no changes in the CSF levels of Aβ1-42 while the 
CSF levels of T-tau increased[90]. Nonetheless, increased postoperative levels of CSF 
Aβ1-42 have been detected 24 hours[42] and 1 week[91] after cardiac surgery. It has 
been speculated that the neuroinflammatory response to major surgery induces pro-
teolysis and cleavage of the amyloid precursor protein, which would increase the level 
of Aβ1-42. A hallmark sign of AD is a low CSF level of Aβ1-42, presumably because 
of sequestration into senile plaques. Low preoperative CSF levels of Aβ1-42 were in 
one study shown to be a predictor of neurocognitive decline at 3 months, and it has 
been suggested that patients with subclinical AD neuropathology are at risk of 
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developing postoperative neurocognitive decline[92]. In our study, we found no dif-
ferences in the preoperative CSF levels of Aβ1-42 between the Good and Poor neu-
rocognitive outcome groups. When applying the clinically used AD cutoff values for 
preoperative CSF Aβ1-42, CSF T-tau and the ratio thereof, there was no association 
with cognitive outcome. 
5.5 Prevention of the neuroinflammatory response 
to major surgery by a corticosteroid (Paper III) 
 
In 2012, Reinsfelt and colleagues reported a pronounced neuroinflammatory re-
sponse to cardiac surgery coupled with disruption of the BBB function[49]. In a later 
MRI study, 47% of the patients showed signs of BBB damage after CABG[51]. This 
could explain the observed development of brain edema after otherwise uncompli-
cated cardiac surgery[93]. Furthermore, cardiac surgery is coupled with a high risk for 
perioperative cerebral microembolization, and this has been proposed as a mecha-
nism for increased BBB permeability[94, 95]. In addition, cerebral oxygen supply/de-
mand mismatch has been proposed as a mechanism for cognitive dysfunction after 
cardiac surgery[94].  
Another possible explanation for the impaired BBB function is an effect of the 
systemic inflammatory reaction triggered by the surgical trauma. Experimental stud-
ies have shown that peripheral surgery induces rapid disruption of the BBB via pro-
inflammatory cytokines, promoting macrophage migration into the CNS[32]. It is 
well-known that cardiac surgery triggers a pronounced systemic inflammatory reac-
tion[55]. This is thought to be a consequence of both a major operation and the 
cardiopulmonary bypass that exposes the blood, and thus the immune system, to a 
large surface of foreign material during extracorporeal circulation. 
In Paper III, we wanted to explore further the neurochemical response to cardiac 
surgery, and whether a perioperative treatment with a potent anti-inflammatory drug 
would modulate the BBB dysfunction and, thus, the postoperative neuroinflamma-
tion. Methylprednisolone is a synthetic corticosteroid with a half-life of 1.7–5.2 hours 
and negligible mineralocorticoid effects. It has been used to counteract the systemic 
inflammatory reaction after cardiac surgery[96] in doses of 15–30 mg/kg adminis-
tered as a single-dose treatment. We found an increased CSF-albumin to serum-albu-
min ratio (i.e., disruption of the BBB function) in both groups, confirming the results 
of Reinsfelt et al. [49]. As there was no significant difference between the groups, we 
concluded that methylprednisolone exerts no protective effect on post-surgical BBB 
dysfunction. 
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There was a pronounced postoperative increase in the serum levels of IL-6 and 
IL-8, corresponding to a systemic inflammatory reaction that predictably was signif-
icantly attenuated in the methylprednisolone-treatment group (Figure 18, Figure 19). 
When it came to evaluating cerebral inflammation, the CSF level of IL-6 showed the 
same pattern as the serum levels of IL-6. However, as the concentrations were lower 
in the CSF this might just reflect a spillover from the blood, thus not proving a re-
duction of neuroinflammation per se.  
To address the question of an ongoing inflammatory reaction within the CNS we 
turned to IL-8. From our previous study[49], we know that there are higher concen-
trations of IL-8 in the CSF, as compared to serum, which would rule out diffusion as 
an explanation and would instead suggest intrathecal production.  
Indeed, the concentration of CSF-IL-8 in the placebo group was higher than the 
serum-IL-8, with a marked increase postoperatively. Much to our surprise, there was 
an even more pronounced increase in CSF-IL-8 after surgery in the methylpredniso-
lone group, indicating exacerbated neuroinflammation after corticosteroid treatment. 
Reports in the literature on the effects of glucocorticoid treatment on CSF-IL-8 pro-
duction after surgery are few and far between. In a study on post-herpetic neuralgia 
treatment with intrathecal injection with methylprednisolone, the CSF level of IL-8 
was reported to be increased 8-fold[97].  
Although there was a small increase in the CSF level of T-tau after surgery in the 
control group, we found no convincing biochemical evidence for neuronal damage, 
as neither the CSF-NSE nor CSF-NFL was affected 24 hours after cardiac surgery, 
supporting the findings of Reinsfelt et al.[49]. There was a small increase in the CSF 
level of S-100B in the methylprednisolone group, and a small increase in the CSF 
level of T-tau in the control group. However, there were no significant between-
group differences. Kaukinen et al. have shown that normothermic or hypothermic 
cardiac surgery with CPB does not induce increased levels of CSF-NSE, measured 
days and months after the procedure[98]. This is in agreement with the results from 
a previous[49] and the present study, showing that that CSF levels of NSE, NFL and 
T-tau are not elevated 24 hours after cardiac surgery.   
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6. Conclusions 
 
I. Major surgery induces a temporary increase in the permeability of the BBB.  
II. Major surgery is associated with pronounced increases in both the systemic 
and CSF levels of inflammatory biomarkers. 
III. The neuroinflammatory biomarkers in patients undergoing orthopedic sur-
gery show a strong correlation to long-term postoperative cognitive decline. 
IV. Orthopedic surgery causes the release of CSF biomarkers of neural injury 
and brain amyloidosis, suggesting neuronal damage or stress. 
V. The CSF and systemic biomarkers of neuronal injury or brain amyloidosis 
in patients undergoing orthopedic surgery show no association to long-term 
postoperative cognitive decline. 
VI. None of the preoperatively measured biomarkers of inflammation, neu-
ronal damage or brain amyloidosis are capable of predicting an unfavorable 
neurocognitive outcome. 
VII. A perioperative single-dose methylprednisolone treatment attenuates the 
systemic inflammatory reaction but does not prevent the postoperative 
BBB dysfunction or the neuroinflammation seen after cardiac surgery 
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7. Future perspectives 
The long-term goal of POCD research should be to develop preventive measures 
and treatment options for this common and potentially devastating condition. In or-
der to accomplish this, the underlying mechanisms need to be understood.  
In Paper I we found a strong association between cerebrospinal inflammatory 
biomarker trajectories and long-term postoperative neurocognitive outcome. How-
ever, the group with poor neurocognitive outcome consisted of mere six patients and 
these findings should therefore, ideally, be validated in a larger study.  
In Paper II there was no association between neither systemic nor cerebrospinal 
markers of neuronal cell damage and postoperative neurocognitive outcome. Alt-
hough the post-hoc power analysis indicated that the sampling size should be large 
enough to detect any relevant difference, the negative result could still be due to an 
underpowered study and thus this should also be addressed in a larger study. Given 
the delayed and protracted release of NFL, an extended sampling period could give 
useful data. 
In Paper III we were unable to prevent the BBB disruption after cardiac surgery 
in the steroid-treatment group. That cytokine-induced changes in BBB permeability 
are involved in post-operative neuroinflammation and cognitive impairment has been 
shown in animal studies[32, 99], and this was prevented when either inhibiting TNF-
α activity or stimulating the cholinergic anti-inflammatory pathway with choline or 
nicotine[32].  In a study of 382 patients undergoing non-cardiac surgery in general 
anesthesia, a history of tobacco-smoking reduced the risk of POCD after 1 
week[100]. Ketamine, an NMDA receptor antagonist, is an anesthetic drug with hyp-
notic and analgesic properties. Ketamine is believed to exert neuroprotective effects 
through a reduction of apoptosis, microthrombosis and inflammation[101]. A recent 
meta-analysis concludes that ketamine treatment seems to reduce the risk of 
POCD[102]. 
To evaluate the preventive effects of pre- / peri-operative anti-TNF, nicotinergic 
and ketamine treatment on BBB function, neuroinflammation and long-term cogni-
tive decline in a larger study seems to me like a worthwhile undertaking. 
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Appendix 
Appendix table 1. List of all 92 inflammatory CSF and blood-borne biomarkers 
Cytokine related  CSF1 Macrophage colony-stimulating factor 1 
Cytokine related  FLT3LG Fms-related tyrosine kinase 3 ligand 
Cytokine related  IFNG Interferon gamma 
Cytokine related  IL10 Interleukin-10  
Cytokine related  IL10RA Interleukin-10 receptor subunit alpha 
Cytokine related  IL10RB Interleukin-10 receptor subunit beta 
Cytokine related  IL12B Interleukin-12 subunit beta 
Cytokine related  IL13 Interleukin-13  
Cytokine related  IL15RA Interleukin-15 receptor subunit alpha 
Cytokine related  IL17A Interleukin-17A 
Cytokine related  IL17C Interleukin-17C 
Cytokine related  IL18 Interleukin-18 
Cytokine related  IL18R1 Interleukin-18 receptor 1 
Cytokine related  IL1A Interleukin-1A 
Cytokine related  IL2 Interleukin-2 
Cytokine related  IL20 Interleukin-20 
Cytokine related  IL20RA Interleukin-20 receptor subunit alpha 
Cytokine related  IL22RA1 Interleukin-22 receptor subunit alpha-1 
Cytokine related  IL24 Interleukin-24  
Cytokine related  IL2RB Interleukin-2 receptor subunit beta 
Cytokine related  IL33 Interleukin-33  
Cytokine related  IL4 Interleukin-4 
Cytokine related  IL5 Interleukin-5 
Cytokine related  IL6 Interleukin-6 
Cytokine related  IL7 Interleukin-7  
Cytokine related  IL8 Interleukin-8 
Cytokine related  LIF Leukemia inhibitory factor  
Cytokine related  LIFR Leukemia inhibitory factor receptor 
Cytokine related  LTA Lymphotoxin-alpha 
Cytokine related  OSM Oncostatin-M  
Cytokine related  SLAMF1 Signaling lymphocytic activation molecule 
Cytokine related  STAMBP STAM-binding protein 
Cytokine related  TGFB1 Transforming Growth Factor β1 
Cytokine related  TNF Tumor necrosis factor  
Cytokine related  TNFRSF11B Tumor necrosis factor receptor superfamily member 
11b 
Cytokine related  TNFRSF9 Tumor necrosis factor receptor superfamily member 9  
Cytokine related  TNFSF10 Tumor necrosis factor superfamily member 10 
Cytokine related  TNFSF11 Tumor necrosis factor superfamily member 11 
Cytokine related  TNFSF12 Tumor necrosis factor superfamily member 12 
Cytokine related  TNFSF14 Tumor necrosis factor ligand superfamily member 14  
Cytokine related TSLP Thymic stromal lymphopoietin 
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Chemokine related CCL11 C-C motif chemokine 11 
Chemokine related CCL13 C-C motif chemokine 13 
Chemokine related CCL19 C-C motif chemokine 19  
Chemokine related CCL2 C-C motif chemokine 2 
Chemokine related CCL20 C-C motif chemokine 20 
Chemokine related CCL23 C-C motif chemokine 23 
Chemokine related CCL25 C-C motif chemokine 25 
Chemokine related CCL28 C-C motif chemokine 28 
Chemokine related CCL3 C-C motif chemokine 3 
Chemokine related CCL4 C-C motif chemokine 4 
Chemokine related CCL7 C-C motif chemokine 7 
Chemokine related CCL8 C-C motif chemokine 8 
Chemokine related CX3CL1 Fractalkine 
Chemokine related CXCL1 C-X-C motif chemokine 1 
Chemokine related CXCL10 C-X-C motif chemokine 10 
Chemokine related CXCL11 C-X-C motif chemokine 11 
Chemokine related CXCL5 C-X-C motif chemokine 5 
Chemokine related CXCL6 C-X-C motif chemokine 6 
Chemokine related CXCL9 C-X-C motif chemokine 9  
Chemokine related KITLG KIT Ligand 
Leukocyte cell surface  CD244 Natural killer cell receptor 2B4 
Leukocyte cell surface  CD274 Programmed cell death 1 ligand 1 
Leukocyte cell surface  CD40 CD40L receptor 
Leukocyte cell surface  CD5 T-cell surface glycoprotein CD5  
Leukocyte cell surface  CD6 T-cell surface glycoprotein CD6 isoform 
Neurotrophic growth factors ARTN Artemin 
Neurotrophic growth factors BDNF Brain-derived neurotrophic factor 
Neurotrophic growth factors FGF19 Fibroblast growth factor 19 
Neurotrophic growth factors FGF21 Fibroblast growth factor 21 
Neurotrophic growth factors FGF23 Fibroblast growth factor 23 
Neurotrophic growth factors FGF5 Fibroblast growth factor 5 
Neurotrophic growth factors GDNF Glial cell line-derived neurotrophic factor 
Neurotrophic growth factors HGF Hepatocyte growth factor 
Neurotrophic growth factors NGF Beta-nerve growth factor 
Neurotrophic growth factors NRTN Neurturin 
Neurotrophic growth factors NTF3 Neurotrophin-3 
Neurotrophic growth factors TGFA Transforming growth factor α  
Neurotrophic growth factors VEGFA Vascular endothelial growth factor A 
Miscellaneous ADA Adenosine Deaminase  
Miscellaneous AXIN1 Axin-1 
Miscellaneous CASP8 Caspase 8 
Miscellaneous CDCP1 CUB domain-containing protein 1 
Miscellaneous CST5 Cystatin D 
Miscellaneous DNER Delta and Notch-like epidermal GF-related recep 
Miscellaneous EIF4EBP1 Eukaryotic translation initiation factor 4E-BP1 
Miscellaneous MMP1 Monocyte chemotactic protein 1  
Miscellaneous MMP10 Matrix metalloproteinase 10 
Miscellaneous PLAU Plasminogen activator, urokinase 
Miscellaneous S100A12 S100 calcium-binding protein A12 
Miscellaneous SIRT2 SIR2-like protein 2  
Miscellaneous SULT1A1 Sulfotransferase family 1A member 1
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